JP2004508333A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004508333A5 JP2004508333A5 JP2002524503A JP2002524503A JP2004508333A5 JP 2004508333 A5 JP2004508333 A5 JP 2004508333A5 JP 2002524503 A JP2002524503 A JP 2002524503A JP 2002524503 A JP2002524503 A JP 2002524503A JP 2004508333 A5 JP2004508333 A5 JP 2004508333A5
- Authority
- JP
- Japan
- Prior art keywords
- quetiapine
- pharmaceutically acceptable
- acceptable salt
- treating
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 description 4
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 4
- 229960004431 quetiapine Drugs 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 206010058314 Dysplasia Diseases 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0003126A SE0003126D0 (sv) | 2000-09-05 | 2000-09-05 | Method of treatment |
| PCT/SE2001/001879 WO2002020019A1 (en) | 2000-09-05 | 2001-08-31 | New use of quetiapine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004508333A JP2004508333A (ja) | 2004-03-18 |
| JP2004508333A5 true JP2004508333A5 (enExample) | 2008-09-04 |
Family
ID=20280890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002524503A Abandoned JP2004508333A (ja) | 2000-09-05 | 2001-08-31 | クエチアピンの新規な用途 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7338948B2 (enExample) |
| EP (1) | EP1326616B1 (enExample) |
| JP (1) | JP2004508333A (enExample) |
| AT (1) | ATE291920T1 (enExample) |
| AU (1) | AU2001282832A1 (enExample) |
| DE (1) | DE60109799T2 (enExample) |
| ES (1) | ES2238469T3 (enExample) |
| PT (1) | PT1326616E (enExample) |
| SE (1) | SE0003126D0 (enExample) |
| WO (1) | WO2002020019A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006073360A1 (en) * | 2005-01-07 | 2006-07-13 | Astrazeneca Ab | NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f] [1,4] THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS |
| US20090035370A1 (en) * | 2007-08-02 | 2009-02-05 | Drugtech Corporation | Dosage form and method of use |
| GB0822077D0 (en) * | 2008-12-03 | 2009-01-07 | Minster Res Ltd | Novel treatments |
| US9993486B1 (en) | 2017-06-19 | 2018-06-12 | Tlc Therapeutics, Llc | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US5605897A (en) | 1991-04-23 | 1997-02-25 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine |
| US5627178A (en) | 1991-04-23 | 1997-05-06 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| GB9611328D0 (en) * | 1996-05-31 | 1996-08-07 | Zeneca Ltd | Pharmaceutical compositions |
-
2000
- 2000-09-05 SE SE0003126A patent/SE0003126D0/xx unknown
-
2001
- 2001-08-31 PT PT01961576T patent/PT1326616E/pt unknown
- 2001-08-31 DE DE60109799T patent/DE60109799T2/de not_active Expired - Fee Related
- 2001-08-31 WO PCT/SE2001/001879 patent/WO2002020019A1/en not_active Ceased
- 2001-08-31 AT AT01961576T patent/ATE291920T1/de not_active IP Right Cessation
- 2001-08-31 ES ES01961576T patent/ES2238469T3/es not_active Expired - Lifetime
- 2001-08-31 JP JP2002524503A patent/JP2004508333A/ja not_active Abandoned
- 2001-08-31 EP EP01961576A patent/EP1326616B1/en not_active Expired - Lifetime
- 2001-08-31 US US10/398,307 patent/US7338948B2/en not_active Expired - Fee Related
- 2001-08-31 AU AU2001282832A patent/AU2001282832A1/en not_active Abandoned
-
2008
- 2008-01-10 US US11/972,350 patent/US20080108597A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2017047I1 (no) | Tofacitinib, evt. i form av et farmasøytisk akseptabelt salt, inkludert citratsalt | |
| JP2003503454A5 (enExample) | ||
| WO2003009838A1 (en) | Use of stilbene compounds in preparing medicaments for treating or preventing diabetes and diseases associated with retrovirus | |
| EP1698329A4 (en) | PHARMACEUTICAL NANOTEILS, METHOD FOR THE PRODUCTION THEREOF AND PARENTERALLY APPLIED PRODUCT FROM NANOTEILES | |
| IL219671A0 (en) | 1,2- benzoxazoles and use thereof in the preparation of a medicament | |
| IL143634A0 (en) | Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament | |
| CA2458067A1 (en) | Use of flibanserin in the treatment of sexual disorders | |
| HUP0401201A3 (en) | Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments | |
| JP2005508963A5 (enExample) | ||
| JP2002542248A5 (enExample) | ||
| EP1440689A3 (en) | Treatment of neurotic disorders | |
| WO2000008007A3 (de) | Cyclopentabenzofuran-derivate und ihre verwendung | |
| NZ502495A (en) | Use of a specific antagonist of 5HT2 receptor antagonist for the preparation of medicines useful in the treatment of sleep apnoea syndrome | |
| JP2004508333A5 (enExample) | ||
| USD448842S1 (en) | Multi-port catheter assembly for a respiratory care system | |
| IL145269A0 (en) | Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders | |
| JP2002542281A5 (enExample) | ||
| DE602005017541D1 (de) | Verfahren zur Herstellung von 1,3,4,5-tetrahydro-2H-3-Benzazepin-2-on-Derivaten und dessen Anwendung in der Herstellung von Ivabradin sowie dessen pharmazeutisch verträglichen Salze | |
| USD450946S1 (en) | Bed | |
| CA2396209A1 (en) | The use of mirtazapine for the treatment of sleep disorders | |
| JP2003522147A5 (enExample) | ||
| JP2003501387A5 (enExample) | ||
| USD545578S1 (en) | Child's chair | |
| USD448843S1 (en) | Multi-port catheter assembly for a respiratory care system | |
| WO2000048582A3 (de) | Pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der drogenabhängigkeit |